---
figid: PMC5988105__iid-0001-0085-g01
figtitle: 'Currently approved and available IBD therapies include: four anti-TNF agents,
  namely infliximab, adalimumab, certolizumab pegol, and golimumab, and two anti-integrin
  agents, natalizumab and vedolizumab'
organisms:
- NA
pmcid: PMC5988105
filename: iid-0001-0085-g01.jpg
figlink: /pmc/articles/PMC5988105/figure/F1/
number: F1
caption: 'The currently approved and available IBD therapies include: four anti-TNF
  agents, namely infliximab, adalimumab, certolizumab pegol, and golimumab, and two
  anti-integrin agents, natalizumab and vedolizumab. Ustekinumab and MEDI2070 are
  human monoclonal IgG antibodies that block the receptor of the p40 subunit of the
  IL-12/23 complex on leukocytes. Etrolizumab is an anti-β7 monoclonal antibody, and
  tofacitinib is a JAK inhibitor in the JAK/STAT pathway. MAdCAM is a gastrointestinal
  addressin that binds α4β7 integrins on leukocytes in the leukocyte recruitment process.
  DC = Dendritic cell; M = microfold cell; TREG cell = regulatory T cells. Reproduced
  with permission from Danese et al. [].'
papertitle: New and Evolving Immunotherapy in Inflammatory Bowel Disease.
reftext: Mohamad A. Raad, et al. Inflamm Intest Dis. 2016 Jul;1(2):85-95.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9413778
figid_alias: PMC5988105__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5988105__F1
ndex: e0d4f333-def4-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5988105__iid-0001-0085-g01.html
  '@type': Dataset
  description: 'The currently approved and available IBD therapies include: four anti-TNF
    agents, namely infliximab, adalimumab, certolizumab pegol, and golimumab, and
    two anti-integrin agents, natalizumab and vedolizumab. Ustekinumab and MEDI2070
    are human monoclonal IgG antibodies that block the receptor of the p40 subunit
    of the IL-12/23 complex on leukocytes. Etrolizumab is an anti-β7 monoclonal antibody,
    and tofacitinib is a JAK inhibitor in the JAK/STAT pathway. MAdCAM is a gastrointestinal
    addressin that binds α4β7 integrins on leukocytes in the leukocyte recruitment
    process. DC = Dendritic cell; M = microfold cell; TREG cell = regulatory T cells.
    Reproduced with permission from Danese et al. [].'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TNF
  - IFN1@
  - IFNA1
  - IFNA2
  - IFNA17
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA21
  - IL10
  - TGFB1
  - TGFB2
  - TGFB3
  - IL12A
  - IL12B
  - CD8A
  - CD8B
  - CD4
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - IL37
  - IL23A
  - MADCAM1
  - ITGA1
  - ITGA10
  - ITGA11
  - ITGA2
  - ITGA2B
  - ITGA3
  - ITGA4
  - ITGA5
  - ITGA6
  - ITGA7
  - ITGA8
  - ITGA9
  - ITGAD
  - ITGAE
  - ITGAL
  - ITGAM
  - ITGAV
  - ITGAX
  - ITGB1
  - ITGB2
  - ITGB3
  - ITGB4
  - ITGB5
  - ITGB6
  - ITGB7
  - ITGB8
  - ITGBL1
  - Crohns disease
---
